Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / EGFL6

EGFL6

Basics

Aliases:
This biomarker is also known as:
  • W80,
  • EGF-like protein 6,
  • Q8IUX8,
  • EGF repeat-containing protein 6,
  • MAM and EGF domains-containing gene protein,
  • MAEG,
  • epidermal growth factor-like protein 6,
  • EGF-like-domain, multiple 6,
  • MAM and EGF domain containing,

View in BioMuta

Description…

EGFL6 is a member of the epidermal growth factor (EGF) repeat superfamily. This family is characterized by EGF-like repeats. Members are involved in the regulation of cell cycle, proliferation, and developmental processes. The presence of a signal peptide indicates it is a secreted protein. The EGFL6 gene is expressed during early development.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: EGFL6

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

EGFL6 is a secreted tumor vascular marker (TVM) that is selectively expressed in tumor vasculature and represents a promising target for vascular imaging or anti-vascular therapy of epithelial ovarian cancer.

Performance Comment

EGFL6 was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of EGFL6 was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.